Objective To explore the efficacy and safety of subcutaneous injection of bortezomib in the treatment of de novo multiple myeloma (MM) patients.Methods A total of 36 MM patients treated with bortezomib,adriamycin and ...Objective To explore the efficacy and safety of subcutaneous injection of bortezomib in the treatment of de novo multiple myeloma (MM) patients.Methods A total of 36 MM patients treated with bortezomib,adriamycin and dexamethason (PAD) from January 2012 to April2013 were analyzed.Among them,18 received improved PAD (improved PAD group) with the subcutaneous injection of bortezomib,another 18 received conventional PAD (PAD group) .The efficacy and safety of two展开更多
Objective To compare the immunophenotypic and clinical characteristics between NPM1mutated acute myeloid leukemia(AML)(NPM1m+AML)and unmutated AML(NPM1m-AML)not otherwise characterized(NOS)
文摘Objective To explore the efficacy and safety of subcutaneous injection of bortezomib in the treatment of de novo multiple myeloma (MM) patients.Methods A total of 36 MM patients treated with bortezomib,adriamycin and dexamethason (PAD) from January 2012 to April2013 were analyzed.Among them,18 received improved PAD (improved PAD group) with the subcutaneous injection of bortezomib,another 18 received conventional PAD (PAD group) .The efficacy and safety of two
文摘Objective To compare the immunophenotypic and clinical characteristics between NPM1mutated acute myeloid leukemia(AML)(NPM1m+AML)and unmutated AML(NPM1m-AML)not otherwise characterized(NOS)
